Invenio Imaging, Inc

Invenio Imaging, Inc specializes in advanced imaging technologies, enhancing surgical pathology with real-time tissue analysis and innovative imaging solutions designed for precise clinical decision-making. Founded in 2012 and headquartered in Menlo Park, US, Invenio Imaging, Inc focuses on providing advanced imaging technologies. The company has undergone significant development, notably through its introduction of groundbreaking products. The founders, Chris Freudiger, Christian Freudiger, and Jay Trautman, have backgrounds in technology and medical imaging, which contribute to the innovation at Invenio.

The company raised USD 1. 00 mn in its most recent funding round on December 29, 2015. Invenio Imaging specializes in advanced imaging technologies that enhance surgical pathology through real-time tissue analysis. The company's core offerings include the NIO Laser Imaging System, which employs Stimulated Raman Histology (SRH) to provide high-resolution imaging of fresh tissue samples in under three minutes.

This innovative approach allows pathologists to visualize cellular features without the need for traditional staining or sectioning, making tissue samples reusable for further analysis. Additionally, the NIO Glioma Reveal, a deep learning-based clinical image analysis algorithm, aids neurosurgeons in identifying cancer infiltration during glioma surgeries, thereby informing intraoperative decisions. Invenio Imaging serves a diverse clientele, including hospitals, surgical centers, and medical professionals, particularly in the fields of neurosurgery, interventional pulmonology, urology, ENT, breast oncology, and organ transplantation. The company’s products are utilized across various regions, including the European Union for NIO Glioma Reveal and other international markets, promoting a global reach in the medical imaging sector.

Invenio Imaging operates on a business-to-business model, primarily engaging with healthcare institutions through direct sales of its imaging systems and software solutions. The company’s transactions typically involve substantial capital expenditures from hospitals and surgical centers that invest in NIO Laser Imaging Systems and related technologies to enhance their diagnostic capabilities. Revenue generation is further supported by partnerships with medical professionals and institutions for research and clinical applications, especially concerning the NIO Glioma Reveal technology. These systems are positioned as premium products within the market, reflecting the advanced capabilities and immediate feedback they provide during surgeries.

While specific pricing structures and revenue figures are not disclosed, the business model suggests a focus on high-value contracts and long-term partnerships with healthcare providers to integrate this imaging technology into surgical workflows. Invenio Imaging plans to expand its product offerings and is currently designing new advancements in imaging technology, targeting a launch within the next year. The company aims to penetrate new geographic markets, particularly within Asia and South America, by 2025. The recent funding of USD 1.

00 mn will support these initiatives, focusing on product development and market entry strategies.